Replies to post #208083 on Biotech Values

[ciotera]

Re: impetus behind MYSTIC change

They are playing it safe now by pre-specifying an endpoint in PD-L1 positive. This is more likely due to what they saw for Nivolumab+Ipilimumab (CM012) rather than Keytruda+carbo+pem (KN021G)

[DewDiligence]

Quiz: In AZN’s phase-3 MYSTIC study in first-line NSCLC, why does the arm testing Durvalumab + Tremelimumab dose the former until disease progression but the latter for only four cycles?

ct.g listing for the trial:
https://www.clinicaltrials.gov/ct2/show/NCT02453282